Mukul Aggarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mukul Aggarwal has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
- Jasmita Dass
Department of Hematology, AIIMS, New Delhi, India
28 shared publications - Manoranjan Mahapatra
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India
25 shared publications - Pradeep Kumar
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
16 shared publications - Amiya Ranjan Nayak
Department of Clinical Hemato-Oncology and BMT, Bagchi Sri Shankara Cancer Center and Research Institute, Bhubaneswar, India
13 shared publications - Ganesh Kumar Viswanathan
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India
13 shared publications - Rishi Dhawan
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
12 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7476-7484
Impact of cytoreductive therapy in myeloproliferative neoplasm–associated splanchnic vein thrombosis
Patients with myeloproliferative neoplasms (MPN) are at risk of splanchnic vein thrombosis (SVT). Previous studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but they are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of patients with MPN-SVT from the international GASTRO-MPN consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of whom 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/transjugular intrahepatic portosystemic shunt thrombosis, and 138 (18%) had a thrombosis recurrence outside the splanchnic bed (74% were venous). In addition, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, previous thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.50-0.89; P = .01). This was driven by a lower risk of SVT extension/recurrence (HR, 0.62; 95% CI, 0.42-0.90; P = .01) but not by extra-splanchnic thrombosis recurrence (HR, 0.97; 95% CI, 0.72-1.30; P = .82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n = 275), cytoreductive therapy was associated with an HR of 0.65 (95% CI, 0.40-1.07; P = .09) for recurrent thrombosis. These data support the use of cytoreductive therapy for patients with MPN-SVT to prevent recurrent thrombosis, particularly SVT extension/recurrence.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7476-7484
Impact of cytoreductive therapy in myeloproliferative neoplasm–associated splanchnic vein thrombosis
Patients with myeloproliferative neoplasms (MPN) are at risk of splanchnic vein thrombosis (SVT). Previous studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but they are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of patients with MPN-SVT from the international GASTRO-MPN consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of whom 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/transjugular intrahepatic portosystemic shunt thrombosis, and 138 (18%) had a thrombosis recurrence outside the splanchnic bed (74% were venous). In addition, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, previous thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.50-0.89; P = .01). This was driven by a lower risk of SVT extension/recurrence (HR, 0.62; 95% CI, 0.42-0.90; P = .01) but not by extra-splanchnic thrombosis recurrence (HR, 0.97; 95% CI, 0.72-1.30; P = .82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n = 275), cytoreductive therapy was associated with an HR of 0.65 (95% CI, 0.40-1.07; P = .09) for recurrent thrombosis. These data support the use of cytoreductive therapy for patients with MPN-SVT to prevent recurrent thrombosis, particularly SVT extension/recurrence.
- Open Access
- 17 November 2026
- Published by Springer Nature in Scientific Reports
SEC23B variants and mRNA expression defects in congenital dyserythropoietic anaemia type II: comprehensive analysis in an Indian cohort
- 17 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessSEC23B variants and mRNA expression defects in congenital dyserythropoietic anaemia type II: comprehensive analysis in an Indian cohort
- 14 November 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- p. 1-6
A Tertiary Care Center Experience of Acquired Hemophilia A
- 14 November 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- p. 1-6
A Tertiary Care Center Experience of Acquired Hemophilia A
- 13 November 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (11) , e271831
Congenital methaemoglobinaemia presenting as polycythaemia caused by a pathogenic CYB5R3 variant
- 13 November 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (11) , e271831
Congenital methaemoglobinaemia presenting as polycythaemia caused by a pathogenic CYB5R3 variant
- 10 November 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- p. 1-5
Non-Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Single-Center Study
- 10 November 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- p. 1-5
Non-Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Single-Center Study
- 27 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (6) , 2187-2207
Indian Consensus Guidelines for the Diagnosis and Management of Aplastic Anemia
- 27 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (6) , 2187-2207
Indian Consensus Guidelines for the Diagnosis and Management of Aplastic Anemia
- 26 August 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (11) , 2372-2375
MLLT10 rearranged acute leukemia-finding order in ambiguity—a case series from a North Indian tertiary care center
Dear EditorMLLT10 fusions, particularly with PICALM as fusion partner, hold prognostic or therapeutic significance as per European LeukemiaNet (ELN) and have been classified under ‘AML, along with ...
- 26 August 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (11) , 2372-2375
MLLT10 rearranged acute leukemia-finding order in ambiguity—a case series from a North Indian tertiary care center
Dear EditorMLLT10 fusions, particularly with PICALM as fusion partner, hold prognostic or therapeutic significance as per European LeukemiaNet (ELN) and have been classified under ‘AML, along with ...